Heterogeneity maintenance in glioblastoma: a social network.

Glioblastoma multiforme (GBM), the most common intracranial tumor in adults, is characterized by extensive heterogeneity at the cellular and molecular levels. This insidious feature arises inevitably in almost all cancers and has great significance for the general outcome of the malignancy, because it confounds our understanding of the disease and also intrinsically contributes to the tumor's aggressiveness and poses an obstacle to the design of effective therapies. The classic view that heterogeneity arises as the result of a tumor's "genetic chaos" and the more contemporary cancer stem cell (CSC) hypothesis tend to identify a single cell population as the therapeutic target: the prevailing clone over time in the first case and the CSC in the latter. However, there is growing evidence that the different tumor cell populations may not be simple bystanders. Rather, they can establish a complex network of interactions between each other and with the tumor microenvironment that eventually strengthens tumor growth and increases chances to escape therapy. These differing but complementary ideas about the origin and maintenance of tumor heterogeneity and its importance in GBM are reviewed here.

[1]  Luke A. Gilbert,et al.  DNA Damage-Mediated Induction of a Chemoresistant Niche , 2010, Cell.

[2]  P. Kleihues,et al.  Predominant Expression of Mutant EGFR (EGFRvIII) is Rare in Primary Glioblastomas , 2004, Brain pathology.

[3]  W. Cavenee,et al.  Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma , 2006, Brain Tumor Pathology.

[4]  M. Greaves Cancer stem cells: back to Darwin? , 2010, Seminars in cancer biology.

[5]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[6]  A. Maleci,et al.  Prostaglandin E2 as an immunomodulating factor released in vitro by human glioma cells , 2004, Acta Neuropathologica.

[7]  Erwin G. Van Meir,et al.  Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor , 1999, Oncogene.

[8]  Michael R. Green,et al.  A Cell-Surface Receptor for Lipocalin 24p3 Selectively Mediates Apoptosis and Iron Uptake , 2005, Cell.

[9]  D. Gutmann,et al.  Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. , 2001, Cancer research.

[10]  P. Black,et al.  αvβ3 and αvβ5 Integrin Expression in Glioma Periphery , 2001 .

[11]  古賀 一成 Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis , 2002 .

[12]  W. Shapiro,et al.  Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. , 1982, Cancer research.

[13]  C. Heldin,et al.  Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.

[14]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[15]  P. Black,et al.  Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. , 2001, Neurosurgery.

[16]  Jian Wang,et al.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells , 2008, International journal of cancer.

[17]  K. Sasaki,et al.  Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. , 1998, Cancer research.

[18]  Mary R. Myerscough,et al.  Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions , 2007, Clinical & Experimental Metastasis.

[19]  I. Fidler,et al.  Metastasis results from preexisting variant cells within a malignant tumor. , 1977, Science.

[20]  Serban Nacu,et al.  A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. , 2010, Cancer cell.

[21]  Yoshitaka Narita,et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.

[22]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[23]  N. Altorki,et al.  TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer , 2010, Proceedings of the National Academy of Sciences.

[24]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[25]  David García-Dorado,et al.  TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. , 2009, Cancer cell.

[26]  A. Aguzzi,et al.  IL-6 is required for glioma development in a mouse model , 2004, Oncogene.

[27]  M. Brada Pathology and Genetics of Tumours of the Nervous System , 2001, British Journal of Cancer.

[28]  H. Colman,et al.  Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway , 2010, Molecular Cancer Therapeutics.

[29]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[30]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .

[31]  W. Shapiro,et al.  Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. , 1981, Cancer research.

[32]  T. Crowe,et al.  Epithelial cells up-regulate matrix metalloproteinases in cells within the same mammary carcinoma that have undergone an epithelial-mesenchymal transition. , 1998, Cancer research.

[33]  J. Huse,et al.  Genetically Engineered Mouse Models of Brain Cancer and the Promise of Preclinical Testing , 2008, Brain pathology.

[34]  D. Tarin,et al.  Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. , 2006, The American journal of pathology.

[35]  K. Nabeshima,et al.  Expression of c‐Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study , 1997, Histopathology.

[36]  J. Herman,et al.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Berens,et al.  Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. , 2007, Journal of the National Cancer Institute.

[38]  D. Bigner,et al.  Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies. , 1983, Cancer research.

[39]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[40]  H. Wiley,et al.  The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.

[41]  J. Moringlane,et al.  Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells. , 1999, Journal of neuropathology and experimental neurology.